Now available ALYMSYS®

 ALYMSYS® (bevacizumab-maly) is a vascular endothelial growth factor inhibitor indicatedfor the treatment of:

• Metastatic colorectal cancer, in combination with intravenous fluorouracil-basedchemotherapy for first- or second-line treatment. (1.1)
• Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- orfluoropyrimidineoxaliplatin- based chemotherapy for second-line treatment inpatients who have progressed on a first-line bevacizumab product-containingregimen. (1.1)

Please see full prescribing information here.